Key result
DES linked to ~44% lower MACE risk vs BMS in STEMI patients undergoing primary PCI.
Why the study?
Does the use of drug eluting stents reduce major adverse cardiac events in patients with STEMI undergoing primary PCI compared to bare metal stents?
Population
370 patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary…
Comparison
Drug eluting stents in the infarct related artery vs Bare metal stents in the infarct related artery
Design
Cohort
Follow-up
median 24 +/- 9 months
Authors
Loading...
DES use was associated with lower TVR and similar thrombosis in this cohort; leaves open whether RCTs will confirm benefit in primary PCI.
Cohort (n=370)
Does the use of drug eluting stents reduce major adverse cardiac events in patients with STEMI undergoing primary PCI compared to bare metal stents?
Hazard Ratio: 0.56 (95% CI 0.3–0.8)
p-value: p=0.01
In a real-world setting, the use of drug-eluting stents during primary PCI for STEMI was safe and significantly reduced MACE, primarily driven by a reduction in target vessel revascularization, compared to bare metal stents.
Romano et al. (2008) conducted a cohort in ST elevation myocardial infarction (STEMI) (n=370). Drug eluting stents (DES) vs. Bare metal stents (BMS) was evaluated on Major adverse cardiac events (MACE): death, reinfarction and target vessel revascularization (TVR) (HR 0.56, 95% CI 0.3-0.8, p=0.01). Drug eluting stents significantly reduced the incidence of major adverse cardiac events compared with bare metal stents in patients with STEMI undergoing primary PCI (HR 0.56; 95% CI 0.3-0.8; P=0.01).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: